Abstract:Pulmonary arterial hypertension (PAH) is a malignant pulmonary vascular syndrome characterized by a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, which eventually leads to right heart failure and even death. Although the exact mechanism of PAH is not fully understood, pulmonary vasoconstriction, vascular remodeling, immune and inflammatory responses, and thrombosis are thought to be involved in the development and progression of PAH. In the era of non-targeted agents, PAH had a very dismal prognosis with a median survival time of only 2.8 years. With the deep understanding of the pathophysiological mechanism of PAH as well as advances in drug research, PAH-specific therapeutic drugs have developed rapidly in the past 30 years, but they primarily focus on the three classical signaling pathways, namely the endothelin pathway, nitric oxide pathway, and prostacyclin pathway. These drugs dramatically improved pulmonary hemodynamics, cardiac function, exercise tolerance, quality of life, and prognosis in PAH patients, but could only reduce pulmonary arterial pressure and right ventricular afterload to a limited extent. Current targeted agents delay the progression of PAH but cannot fundamentally reverse pulmonary vascular remodeling. Through unremitting efforts, new therapeutic drugs such as sotatercept have emerged, injecting new vitality into this field. This review comprehensively summarizes the general treatments for PAH, including inotropes and vasopressors, diuretics, anticoagulants, general vasodilators, and anemia management. Additionally, this review elaborates the pharmacological properties and recent research progress of twelve specific drugs targeting three classical signaling pathways, as well as dual-, sequential triple-, and initial triple-therapy strategies based on the aforementioned targeted agents. More crucially, the search for novel therapeutic targets for PAH has never stopped, with great progress in recent years, and this review outlines the potential PAH therapeutic agents currently in the exploratory stage to provide new directions for the treatment of PAH and improve the long-term prognosis of PAH patients.

Atrial flow regulators for the treatment of pulmonary arterial hypertension: what does the future hold?

Endothelial Progenitor Cell-Based Therapy for Pulmonary Arterial Hypertension

The Future of PAH Treatment

Risk stratification and medical therapy of pulmonary arterial hypertension

Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension

Treatment algorithm for pulmonary arterial hypertension

Transplantation, bridging, and support technologies in pulmonary hypertension

Use of Pulmonary Arterial Hypertension Therapies in Patients with a Fontan Circulation: Current Practice Across the United Kingdom

Mechanisms and treatment of pulmonary arterial hypertension

Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children

Risk stratification and treatment goals in pulmonary arterial hypertension

Diagnosis and treatment of pediatric pulmonary arterial hypertension

Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension

A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function

Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?

Pharmacotherapy of refractory pulmonary arterial hypertension

Future Perspectives of Pulmonary Arterial Hypertension: A Review of Novel Pipeline Treatments and Indications

Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs

Current Management and Future Directions for Pulmonary Arterial Hypertension Associated with Congenital Heart Disease

Pulmonary arterial hypertension: pharmacologic therapies and potential pulmonary artery denervation treatment.

Contemporary Treatment of Pulmonary Arterial Hypertension: A U.S. Perspective